Engineering patient-specific cancer immunotherapies
Open accessAbstract
Research into the immunological processes implicated in cancer has yielded a basis for the range of immunotherapies that are now considered the fourth pillar of cancer treatment (alongside surgery, radiotherapy and chemotherapy). For some aggressive cancers, such as advanced non-small-cell lung carcinoma, combination immunotherapies have resulted in unprecedented treatment efficacy for responding patients, and have become frontline therapies. Individualized immunotherapy, enabled by the identification of patient-specific mutations, neoantigens and biomarkers, and facilitated by advances in genomics and proteomics, promises to broaden the responder patient population. In this Perspective, we give an overview of immunotherapies leveraging engineering approaches, including the design of biomaterials, delivery strategies and nanotechnology solutions, for the realization of individualized cancer treatments such as nanoparticle vaccines customized with neoantigens, cell therapies based on patient-derived dendritic cells and T cells, and combinations of theranostic strategies. Developments in precision cancer immunotherapy will increasingly rely on the adoption of engineering principles.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Deep Reinforcement Learning (DRL) combines reinforcement learning and deep neural networks and combines the advantages of both.
“DRL combines both reinforcement learning and deep neural networks algorithms and combines the advantages of both [37].”
From 6G Communication Technology: A Vision on Intelligent Healthcare (2021) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 189 · Cited by 208
- Authors
- Scheetz, L., Park, K. S., Li, Q., Lowenstein, P. R., Castro, M. G., Schwendeman, A., & Moon, J. J.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Moon, James J.
- Venue
- Nature Biomedical Engineering
- Published
- 2019-08-12
- Volume
- 3
- Issue
- 10
- Pages
- 768-782
- ISSN
- 2157-846X (ISSN-L)
- PMC
- PMC6783331
- OpenAlex
- W2967618321
- Cited by
- 208
- References
- 189
- Citations by year
- 2026: 14 · 2025: 27 · 2024: 50 · 2023: 35 · 2022: 21 · 2021: 34 · 2020: 26 · 2019: 1
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature Biomedical Engineering (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA210273, R01CA223804, U01CA210152)
- U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01EB022563)
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL134569)
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI127070)
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R21NS091555)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- cancer immunotherapy, neoantigens, biomaterials, nanoparticle vaccine, dendritic cell immunotherapy, T cell engineering, theranostics, biomarker discovery, non-small cell lung cancer, combination immunotherapy, precision oncology
- MeSH terms
- Theranostic Nanomedicine, Algorithms, Animals, Antigens, Neoplasm, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Dendritic Cells, Drug Therapy, Drug Therapy, Combination, Genetic Vectors, Humans, Immunotherapy, Mutation, Phototherapy, T-Lymphocytes, Biomarkers, Tumor, Vaccines, Synthetic, Drug Delivery Systems, Cancer Vaccines, Nanotechnology, Nanoparticles, Precision Medicine, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
